Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZHONGCHAOZCMD -4.21%47 EV-to-EBIT is 0.73 as of Aug. 31, 2026, which is 43% below its 10-year median of 1.28. GuruFocus rates ZCMD with a GF Score™ of 47/100 and a GF Value™ of $114.09 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 477 Healthcare Providers & Services companies, ZHONGCHAO ranks better than 97.27% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ZHONGCHAO's Enterprise Value for the quarter that ended in Dec. 2025 was $3.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ZHONGCHAO's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZHONGCHAO EV-to-EBIT Related Terms
ZHONGCHAO EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for ZHONGCHAO's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, ZHONGCHAO's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZHONGCHAO EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ZHONGCHAO's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ZHONGCHAO's EV-to-EBIT falls into.
ZHONGCHAO's current Enterprise Value is $-4.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ZHONGCHAO's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZHONGCHAO (ZCMD) has a EV-to-EBIT of 0.73 as of Aug. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ZHONGCHAO and its competitors. This is 43% below median its historical median of 1.28. According to the industry distribution chart, ZHONGCHAO ranks #13 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 2.7%.
Is ZHONGCHAO's EV-to-EBIT too high?
ZHONGCHAO's current EV-to-EBIT of 0.73 is 43% below median its 10-year median of 1.28. The Healthcare Providers & Services industry median EV-to-EBIT is 15.73. ZHONGCHAO's value of 0.73 is 95.4% below this industry median. Based on the distribution chart, ZHONGCHAO ranks #13 out of 477 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, ZHONGCHAO has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ZHONGCHAO's EV-to-EBIT compare to ACON and BRGX?
According to the Healthcare Providers & Services industry distribution chart, ZHONGCHAO ranks #13 out of 477 companies for EV-to-EBIT. This places ZHONGCHAO in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.73. ZHONGCHAO's value of 0.73 is 95.4% below this benchmark. While the company's 10-year median is 1.28 vs. the industry median of 15.73, ZHONGCHAO has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.73, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ZHONGCHAO's current EV-to-EBIT of 0.73 is 95.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ZHONGCHAO and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZHONGCHAO's current EV-to-EBIT is 0.73, which is 43% below median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZHONGCHAO stock overvalued right now?
Based on GuruFocus' analysis, ZHONGCHAO (ZCMD) is currently considered Possible Value Trap. The stock's GF Value™ is $114.09, compared to a current price of $0.88 — trading 99.2% below its estimated fair value. The current EV-to-EBIT is 0.73, which is 43% below median its 10-year median of 1.28 and 95.4% below the Healthcare Providers & Services industry median of 15.73. ZHONGCHAO's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ZHONGCHAO (ZCMD), the current EV-to-EBIT is 0.73 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ZHONGCHAO (ZCMD) Overvalued in 2026?
Based on GuruFocus' analysis, ZHONGCHAO stock appears to be undervalued.
The current stock price of $0.88 is trading 99.2% below its estimated GF Value™ of $114.09.
GuruFocus considers ZHONGCHAO to be Possible Value Trap.
Key valuation signals for ZCMD:
EV-to-EBIT: 0.73 (43% below median its 10-year median of 1.28)
GF Value™: $114.09 vs. price of $0.88 (99.2% below fair value)
Industry Position: 95.4% below the Healthcare Providers & Services median (#13 of 477)
No single metric tells the full story. See the ZCMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
47GF Score
Get the complete analysis for ZCMD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZCMD has been successfully added to your 
